TScan Therapeutics Inc (TCRX)
7.78
-0.23
(-2.87%)
USD |
NASDAQ |
May 09, 16:00
7.785
0.00 (0.00%)
After-Hours: 20:00
TScan Therapeutics Debt to Equity Ratio: 0.1992 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.1992 |
| September 30, 2023 | 0.1772 |
| June 30, 2023 | 0.1559 |
| March 31, 2023 | 0.3782 |
| December 31, 2022 | 0.2946 |
| September 30, 2022 | 0.2492 |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
0.3782
Maximum
Mar 2023
0.1119
Average
--
Median
Dec 2020
Debt to Equity Ratio Benchmarks
| AnaptysBio Inc | 0.00 |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.00 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 0.3431 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 272.15M |
| Total Liabilities (Quarterly) | 121.28M |
| Shareholders Equity (Quarterly) | 150.87M |
| Current Ratio | 6.514 |
| Net Debt Paydown Yield | -0.07% |